✦ LIBER ✦

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

✍ Scribed by Patrick Schöffski; Ahmad Awada; Herlinde Dumez; Thierry Gil; Sylvie Bartholomeus; Pascal Wolter; Martine Taton; Holger Fritsch; Patricia Glomb; Gerd Munzert

Book ID: 116430931
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 245 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.11.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

36 ORAL A Phase I single dose escalation

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

✍ P. Schöffski; A. Awada; H. Dumez; T. Gil; S. Bartholomeus; J. Selleslach; M. Tat 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Phase I dose escalation study of MK-0457

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

✍ Anne M. Traynor; Maureen Hewitt; Glenn Liu; Keith T. Flaherty; Jason Clark; Stev 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 252 KB

Phase I dose-escalation study of F60008,

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

✍ J.J.E.M. Kitzen; M.J.A. de Jonge; C.H.J. Lamers; F.A.L.M. Eskens; D. van der Bie 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 495 KB

A phase I dose-escalation study of the i

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours

✍ Silke Gillessen; Ulrike S. Gnad-Vogt; Elisa Gallerani; Joachim Beck; Cristiana S 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 400 KB

Phase I dose escalation study of telatin

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

✍ Strumberg, D; Schultheis, B; Adamietz, I A; Christensen, O; Buechert, M; Kraetzs 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Phase I Study of GSK461364, a Specific a

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

✍ Olmos, D.; Barker, D.; Sharma, R.; Brunetto, A. T.; Yap, T. A.; Taegtmeyer, A. B 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 988 KB